Cover Image

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class

Saved in:

Bibliographic Details
Main Authors:	Ahmed Bagit, BSc (Author), Khalad Maliyar, MD (Author), Jorge R. Georgakopoulos, MD (Author), Brian Rankin, BSc (Author), Alexander Rimke, MSc (Author), Asfandyar Mufti, MD (Author), Heather Le, CRC (Author), Ronald Vender, MD (Author), Vimal H. Prajapati, MD (Author), Jensen Yeung, MD (Author)
Format:	Book
Published:	Elsevier, 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023)

Use of sulfasalazine for psoriasis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
by: Siddhartha Sood, HBSc, et al.
Published: (2023)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
by: Yuliya Lytvyn, PhD, et al.
Published: (2021)

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

COVID-19 and wound care: A Canadian perspective
by: Asfandyar Mufti, MD, et al.
Published: (2020)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23
by: Madison Ward, BSc, MD, et al.
Published: (2021)

Acquired perforating dermatosis associated with risankizumab
by: Munira Alhadlg, MD, et al.
Published: (2024)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
by: Muskaan Sachdeva, BHSc, et al.
Published: (2021)

Risankizumab-associated lichen planus pemphigoides
by: Jessica Sparks, et al.
Published: (2023)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
by: Fabrizio Martora, MD, et al.
Published: (2023)

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma
by: Georgia Koroneos, BSc, MD, et al.
Published: (2024)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review
by: Siddhartha Sood, HBSc, et al.
Published: (2023)

Modified dose of guselkumab for treatment of pyoderma gangrenosum
by: Ashley M. Reese, BS, et al.
Published: (2022)

Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study
by: Pierre-Dominique Ghislain, MD, et al.
Published: (2021)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
by: Kanako Tsunoda, MD, PhD, et al.
Published: (2024)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
by: Cara Barber, MD, MPH, et al.
Published: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary
by: Tamara Gracia Cazaña, MD, PhD, et al.
Published: (2024)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
by: Ronald Vender, MD, et al.
Published: (2022)

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma
by: George D. Glinos, MD, et al.
Published: (2021)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum
by: Cassandra Baier, MS, PA-C, et al.
Published: (2021)

Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
by: Richard G. Langley, MD, et al.
Published: (2024)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literatureCapsule Summary
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series
by: Michelle Phung, BMSc, et al.
Published: (2018)

Management of Failed Latarjet Procedure Using a Distal Clavicular Autograft
by: Sharon Abihssira MD, et al.
Published: (2022)

Methotrexate-induced cutaneous ulceration and necrosis in chronic atopic dermatitis
by: Malika A. Ladha, MD, et al.
Published: (2020)

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
by: Jorge R. Georgakopoulos, MD, et al.
Published: (2021)

Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations
by: Marcia Leung MD, et al.
Published: (2020)

Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports
by: Khalid Nabil Nagshabandi, MBBS, et al.
Published: (2023)